lerodalcibep
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolemia
Conditions
Heterozygous Familial Hypercholesterolemia
Trial Timeline
Apr 22, 2021 → Dec 5, 2023
NCT ID
NCT04797104About lerodalcibep
lerodalcibep is a phase 3 stage product being developed by Medpace for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04797104. Target conditions include Heterozygous Familial Hypercholesterolemia.
What happened to similar drugs?
1 of 14 similar drugs in Heterozygous Familial Hypercholesterolemia were approved
Approved (1) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05234775 | Phase 3 | Completed |
| NCT04797104 | Phase 3 | Completed |
| NCT04797247 | Phase 3 | UNKNOWN |
| NCT04806893 | Phase 3 | UNKNOWN |
| NCT04798430 | Phase 3 | Recruiting |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 44 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 40 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 45 |
| Inclisiran | Novartis | Phase 3 | 44 |
| Inclisiran + Placebo | Novartis | Phase 3 | 40 |
| Fluvastatin | Novartis | Phase 3 | 40 |
| Inclisiran + Placebo | Novartis | Phase 3 | 47 |
| Evolocumab + Placebo | Amgen | Phase 3 | 40 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 40 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 29 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 40 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 40 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 40 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 40 |
| Praluent | Sanofi | Approved | 35 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 35 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 37 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 32 |